Group 1 - The core point of the article is that Aojing Medical (688613.SH) has received a notice from Qilun Tianyou regarding a share reduction plan [1] - Qilun Tianyou plans to reduce its holdings in Aojing Medical by up to 1.3555 million shares, which represents 1% of the total shares of Aojing Medical [1]

奥精医疗科技股份有限公司 证券代码：688613 证券简称：奥精医疗 公告编号：2025-052 关于持股 5%以上股东权益变动至 5%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2025 年 9 月 23 日收到公司股东 BioVeda 发来的《奥精医疗科技股 份有限公司简式权益变动报告书》，现将其有关权益变动情况公告如下： 一、本次权益变动情况 | （一）信息披露义务人基本情况 | | --- | | 企业名称 | BioVeda | China | RMB | Investment | | Limited | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 注册地址 | 3806 | Central | Plaza, | 18 | Harbour | Road, | Wanchai | HK | | 执行事务合伙人 | 不适用 | | | | | | | | | 成立时间 | 2008年9月30日 | ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-053 奥精医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东的基本情况 大股东最近一次减持情况 股东名称 减持数量 （股） 减持比例 减持期间 减持价格区间 （元/股） 前期减持计划 披露日期 奇伦天佑 600,000 0.449% 2023/4/21～ 2023/7/11 28.00-29.30 2023.3.21 二、减持计划的主要内容 股东名称 奇伦天佑 计划减持数量 不超过：1355515 股 计划减持比例 不超过：1% 减持方式及对应减持数 量 集中竞价减持，不超过：1355515 股 大宗交易减持，不超过：1355515 股 减持期间 2025 年 10 月 23 日～2026 年 1 月 23 日 拟减持股份来源 IPO 前取得 拟减持原因 自身资金安排 截至本公告披露日，奥精医疗科技股份有限公司（以下简称 "公司" 或"奥精医疗"）股东北京奇伦天佑创业投资有限公司（以 ...

奥精医疗科技股份有限公司 简式权益变动报告书 信息披露义务人：BioVeda China RMB Investment Limited 股份变动性质：减持股份 签署日期：2025年9月23日 1 上市公司：奥精医疗科技股份有限公司 上市地点：上海证券交易所 股票简称：奥精医疗 股票代码：688613 信息披露义务人声明 一、本权益变动报告书是依据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披 露内容与格式准则第 15 号——权益变动报告书》《公开发行证券的公司信 息披露内容与格式准则第 16 号——上市公司收购报告书》及相关法律、法 规、规范性文件之规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的 规定，本报告书已全面披露信息披露义务人在奥精医疗科技股份有限公司 拥有权益的股份变动情况。截至本报告书签署之日，除本报告书披露的持 股信息外，上述信息披露义务人没有通过任何其他方式增加或减少其在奥 精医疗科技股份有限公司中拥有权益的股份。 四、信息披露义务人承诺本报告书不存在虚假记载 ...

Group 1 - The core point of the article is that Beijing Qilun Tianyou Venture Capital Co., Ltd., a shareholder holding 6.18% of Aojing Medical (688613), plans to reduce its stake by up to 1% through centralized bidding and block trading, amounting to no more than 1.3555 million shares [1]

Group 1 - The core point of the article is that Beijing Qilun Tianyou Venture Capital Co., Ltd. plans to reduce its stake in Aojing Medical Technology Co., Ltd. by up to approximately 1% of the total shares, which amounts to about 136 million shares [1] - As of the announcement date, Qilun Tianyou holds approximately 8.47 million shares, representing 6.18% of Aojing Medical's total shares [1] - The shares to be reduced were acquired before the company's initial public offering and have been tradable since May 23, 2022 [1] Group 2 - The reduction will be executed through centralized bidding and block trading, with specific timelines for each method [1] - The centralized bidding reduction will take place within three months after the 15 trading days following the announcement, while the block trading will follow the same timeline [1]

Group 1 - The core point of the article is that BioVeda China RMB Investment Limited has reduced its stake in Aojing Medical by selling 388,900 shares, bringing its total holdings to 6.8504 million shares, which now represents 5% of the company's total equity, down from 5.28% [1] - The reduction in shareholding was a voluntary decision made by the shareholder based on its own funding needs, and there is a possibility of further reductions within the next 12 months [1] - The shares held by the shareholder are not subject to any pledges or restrictions such as freezing [1]

奥精医疗公告，股东北京奇伦天佑创业投资有限公司持有公司846.8万股，占6.18%，计划通过集中竞 价、大宗交易方式减持不超过135.55万股，即不超过1%，减持期为2025年10月23日至2026年1月23日， 减持原因为自身资金安排。 ...

Summary of Key Points Core Viewpoint - Aojing Medical (688613) has seen a notable increase in stock price, closing at 27.13 yuan as of September 19, 2025, which is a 4.75% rise from the previous week [1]. Trading Information - On September 16, Aojing Medical recorded a significant block trade with institutional net purchases amounting to 9.83 million yuan. - On September 15, another block trade occurred with institutional net purchases of 9.21 million yuan. - Over the two days, the total institutional net purchases reached 19.04 million yuan [1][3]. Company Announcements - Aojing Medical held its second extraordinary general meeting of shareholders on September 15, 2025, where a legal opinion was provided by Beijing Zhonglun Law Firm. - The meeting approved the proposal to supplement the non-independent director of the second board of directors. - A total of 48 shareholders and authorized agents attended the meeting, representing 21,634,885 shares, which is 15.79% of the total share capital on the record date [1].

近5日融资融券数据一览见下表： 证券之星消息，截至2025年9月17日收盘，奥精医疗(688613)报收于27.8元，下跌2.52%，换手率 7.11%，成交量9.74万手，成交额2.71亿元。 9月17日的资金流向数据方面，主力资金净流入2625.12万元，占总成交额9.68%，游资资金净流出 954.34万元，占总成交额3.52%，散户资金净流出1670.78万元，占总成交额6.16%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-17 | 27.80 -2.52% | | 2625.12万 | 9.68% | -954.34万 | -3.52% | -1670.78万 | -6.16% | | 2025-09-16 | 28.52 | 6.78% | -1487.58万 | -3.13% | 1582.69万 | 3.33% | -95.11万 | -0.20% | | ...